Y Balagula1, S Wu, X Su, M E Lacouture. 1. Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022, USA.
Abstract
BACKGROUND: The effect of chemotherapy on the risk of cetuximab-induced acneiform rash is unknown. We carried out a systematic review and meta-analysis of published studies to quantify the incidence and risk of high-grade acneiform rash with combination therapy. METHODS: Relevant studies were identified from PubMed database, abstracts presented at the American Society of Clinical Oncology conferences, and Web of Science. Incidence of acneiform rash to cetuximab monotherapy was estimated based on updated data from our previously published meta-analysis. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated based on the heterogeneity of included studies. RESULTS: A total of 5333 patients from nine trials were included in the analysis. The incidence of high-grade acneiform rash was significantly increased in patients receiving combination treatment (12.8%, 95% CI 9.1% to 17.7%) as compared with cetuximab monotherapy (6.3%, 95% CI 3.7% to 10.5%), with a risk ratio of 2.03 (95% CI 1.52-2.71, P < 0.01). Cetuximab significantly increased the risk of high-grade rash in patients receiving combination therapy (RR = 37.7, 95% CI 17.8-80.0, P < 0.001). CONCLUSIONS: Addition of cytotoxic chemotherapy to cetuximab significantly increases the risk of high-grade acneiform rash compared with cetuximab monotherapy. This emphasizes the need for effective management strategies.
BACKGROUND: The effect of chemotherapy on the risk of cetuximab-induced acneiform rash is unknown. We carried out a systematic review and meta-analysis of published studies to quantify the incidence and risk of high-grade acneiform rash with combination therapy. METHODS: Relevant studies were identified from PubMed database, abstracts presented at the American Society of Clinical Oncology conferences, and Web of Science. Incidence of acneiform rash to cetuximab monotherapy was estimated based on updated data from our previously published meta-analysis. Incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated based on the heterogeneity of included studies. RESULTS: A total of 5333 patients from nine trials were included in the analysis. The incidence of high-grade acneiform rash was significantly increased in patients receiving combination treatment (12.8%, 95% CI 9.1% to 17.7%) as compared with cetuximab monotherapy (6.3%, 95% CI 3.7% to 10.5%), with a risk ratio of 2.03 (95% CI 1.52-2.71, P < 0.01). Cetuximab significantly increased the risk of high-grade rash in patients receiving combination therapy (RR = 37.7, 95% CI 17.8-80.0, P < 0.001). CONCLUSIONS: Addition of cytotoxic chemotherapy to cetuximab significantly increases the risk of high-grade acneiform rash compared with cetuximab monotherapy. This emphasizes the need for effective management strategies.
Authors: Roberta Grande; Filomena Narducci; Sara Bianchetti; Giovanni Mansueto; Donatello Gemma; Isabella Sperduti; Giorgio Trombetta; Franco Angelini; Teresa Gamucci Journal: Support Care Cancer Date: 2013-01-13 Impact factor: 3.603
Authors: Voichita Bar-Ad; Qiang Ed Zhang; Paul M Harari; Rita Axelrod; David I Rosenthal; Andy Trotti; Christopher U Jones; Adam S Garden; Guobin Song; Robert L Foote; David Raben; George Shenouda; Sharon A Spencer; Jonathan Harris; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-26 Impact factor: 7.038